Digital Biomarkers Market Insights, Growth & Opportunity Outlook, 2024-2035: Quibim’s QP-Brain Leads Neurodegenerative Disorder Detection, AliveCor’s KardiaMobile Card Cleared for Rapid ECG Diagnosis –

DUBLIN–(BUSINESS WIRE)–The “Digital Biomarkers Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Product, Purpose of Solution, Type of Biomarker, Therapeutic Area, Business Model and Key Geographical Regions” report has been added to’s offering.

The global digital biomarkers market is estimated to be USD 5.55 billion in 2024 and is projected to reach USD 35.8 billion in 2035. The market is anticipated to grow at a CAGR of 18.5% during the forecast period 2024-2035. The conventional approach of manually tracking the health data of individuals is associated with several challenges, including delay in timely assessment of critical health information, susceptibility to errors, time and cost-intensive process, and risk of loss / damage of health records, thereby hindering timely treatment of patients (specifically the aging population). It is estimated that 65% of hospital patients and more than 90% of post-acute care patients are manually tracked for vitals and patient-specific parameters every four to eight hours. As a result, there has been a rising prominence of telemedicine that leverages digital tools in order to provide remote consultations and services.

Notably, digital health technologies enable continuous patient monitoring, thereby allowing health practitioners to timely track the baseline changes in individual patients. Additionally, the implementation of continuous monitoring systems has proven to significantly reduce adverse events and hospital re-admissions. The growing field of digital biomarkers as well as digital therapeutics are a part of the broader digital health market.

Further, as per the World Health Organization, by 2030, one-sixth of the global population will be aged over 60 years. Hence, detecting their symptoms proactively at an early stage is intuitively better than treating patients who are seriously ill (due to longer waiting time). Studies have shown that continuous symptom tracking with early intervention has not only led to remarkable improvement in quality of life of patients, but also led to reduced healthcare costs.

The rising digitalization in the healthcare industry has led to the development of several digital solutions that are capable of generating, collecting and tracking medical information (via biomarkers in the body). Digital solutions for biomarkers are defined as digital devices (such as smartphones, sensors and wearable devices) that measure / quantify the physiological and behavioral or biometric data (including blood pressure, emotional health, heart rate, glucose level, physical activity, respiratory function and sleep pattern).

These advanced solutions enable real-time monitoring of an individual’s health (specifically in chronic disease management), encourage proactive participation of individuals in wellness activities, and allow personalized healthcare by tailoring the treatments based on individual data. With the rising prevalence of chronic diseases, growing emphasis on remote patient monitoring and continuous advancements in the technologies, the digital biomarkers market size is prepared for growth in the foreseen future.

Digital Biomarkers Market Segmentation Overview

Market Share by Type of Product

The digital biomarkers market highlights the market segmentation of digital biomarkers, based on the type of product, into software / applications, wearables, sensors and gaming solutions. Currently, the wearables market segment captures maximum share (50%) of the overall market; this can be attributed to the shifting preference of patients towards virtual consultations and telemedicine, leading to an increased demand for technologies that can monitor patients remotely. However, the market for sensors is likely to grow at a relatively faster pace in the next decade.

Market Share by Purpose of Solution

The digital biomarkers market highlights the market segmentation of digital biomarkers, based on the purpose of solution, into diagnosis, early detection, monitoring, and predictive insights. Currently, the monitoring segment captures the highest share of the market and is expected to dominate during the forecast period. Further, the digital biomarker solutions market for predictive insights is anticipated to capture 30% of the overall market in 2035, owing to the likely advancements in artificial intelligence and machine learning based technologies for predicting patient outcomes based on large amounts of historical data.

Market Share by Type of Biomarker

The digital biomarkers market is segmented, based on the type of biomarker, into cognitive, idiosyncratic, physiological, vocal, and other biomarkers. The digital biomarker solutions that capture physiological biomarkers occupy the highest market share in 2024; this can be attributed to availability of clinically validated data on reliability of physiological biomarkers. Further, the vocal digital biomarkers segment is expected to witness substantial market growth in the coming years.

Market Share by Therapeutic Area

The digital biomarkers market highlights various therapeutic areas such as autoimmune disorders, cardiovascular disorders, infectious diseases, mental health disorders, neurological disorders, respiratory disorders, substance abuse disorders and others. Among these segments, the market for neurological disorders is likely to capture the highest market share, followed by mental health disorders.

Market Share by Key Geographical Regions

This segment highlights the distribution of digital biomarkers market across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa (MENA) and Rest of the World. According to the projections, North America is likely to capture the majority share (44%) of this market, and this trend is unlikely to change in the future as well. It is worth highlighting that the market in Asia-Pacific is expected to grow at a CAGR of 21.8%, during the forecast period 2024-2035.

Digital Biomarkers Market Key Insights

The market report features an extensive study of the current market landscape, market size and future opportunities for digital biomarker companies during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the global digital biomarkers market report are briefly discussed below.

Competitive Landscape of Digital Biomarkers

The digital biomarkers market features over 220 digital biomarkers. A majority (80%) of these solutions are software / applications which digitally identify various types of biomarkers. Further, over 75% of the solutions are data collection tools which capture biomarker data via various types of sensors, including accelerometers, cameras, spirometers and temperature sensors. It is noteworthy that more than 25% of the digital biomarkers detect / monitor physiological biomarkers, while close to 20% of these solutions are used as imaging biomarkers, for analyzing images and scans. In addition, a majority (60%) of the digital biomarkers are used for monitoring patients suffering from wide range of diseases.

The current market landscape features the presence of more than 125 developers of digital biomarkers across the globe. Overall, the market seems to be dominated by the presence of small and very small digital biomarker companies. Notably, 50% of the companies in the digital biomarkers industry are based in North America, followed by companies-based Europe (39%).

Emergence of Artificial Intelligence in the Digital Biomarkers Market

During the research, we came across nearly 135 digital biomarker solutions that integrate artificial intelligence-based algorithms to detect / monitor numerous biomarkers. More than 40% of these solutions are currently under research and development while around 25% of these are approved by the regulatory agencies. It is worth highlighting that, in December 2023, Quibim announced the launch of QP-Brain, FDA 510(k) cleared, and CE marked artificial intelligence (AI)-based software for the detection of early-stage neurodegenerative disorders. In February 2022, AliveCor received FDA clearance for its KardiaMobile Card, which provides medical grade ECG in 30 seconds, thereby allowing for early diagnosis of cardiac arrhythmias.

Digital Biomarkers Transforming Treatment for Neurological Disorders and Other Indications

Currently, the digital biomarker solutions are intended for applications across a plethora of disease indications; over 35% of the solutions are neurological digital biomarkers that are used for monitoring patients with different neurological disorders, including attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, dementia, epilepsy and Parkinson’s disease. It is worth noting that Akili Interactive’s EndeavorRxT is a unique video game-based prescription treatment useful for children with ADHD. Further, several innovative digital solutions are currently available / being developed for cardiovascular and oncological disorders.

Digital Biomarkers in Clinical Trials

Recent emergence of digital technologies in healthcare, increasing number of decentralized clinical trials and the increasing adoption of such technologies among consumers has led to increased research in this domain (to further identify relevant clinical end-points). The ANeED Joint Effort 21 clinical study aims to develop predictive algorithms to detect disease fluctuations in lewy-body dementia patients. In addition, the DreaMS clinical study was designed to evaluate the feasibility of the DreaMS app, which collected patient health data via smartphone sensors and wearable devices for monitoring patients with Multiple Sclerosis.

Digital Biomarkers Market Trends: Partnerships and Collaborations on the Rise for Digital Biomarker Solutions

In recent years, several partnerships have been inked by the industry stakeholders in order to consolidate their presence in this field. It is worth highlighting that nearly 25% of deals have been forged since 2023. Interestingly, most of the agreements (21%) were product / technology integration agreements, followed by product / technology utilization agreements (16%). In November 2023, Oura entered into an agreement with Clue in order to offer integrated services to their customers, wherein the Oura ring could be paired with the Clue app for tracking health parameters.

Market Trends: Upward Trend in Funding and Investments for Digital Biomarkers

Several stakeholders in this domain have raised funds in order to fuel their growth operations. It is noteworthy that companies offering digital biomarker solutions have raised a cumulative sum of more than USD 1.6 billion, since 2022. Further, majority of the funding instances are venture capital investments (46%), followed by grants (24%) and seed funding (20%). In September 2023, BioSensics received a grant worth USD 3 million, from the National Institutes of Health (NIH) for development of a wearable device designed for tracking vocal biomarkers.

Market Trends: Increasing Number of Global Events for Digital Biomarkers

Since 2021, more than 55 global events have been organized across the globe for discussing the innovations being made in the field of digital biomarkers. A majority (36%) of the events held were conferences, followed by summits (33%). Further, the agenda of many of these events was to discuss the results of digital biomarker focused clinical trials. Notably, artificial intelligence (AI) was an important topic that was conversed about in multiple events.

Market Trends: Surge in the Number of Patent Applications for Digital Biomarkers

In the past five years, over 765 patents focused on digital biomarkers have been granted / filed, indicating the substantial efforts made by the researchers in this market. It is worth highlighting that a majority of the patents (70%) in this domain were patent applications (not having received approval yet), followed by granted patents (27%). Further, most of the patents have been filed by non-academic players in this industry.

Digital Biomarkers Market Analysis

The digital biomarkers market is estimated to be worth USD 5.55 billion in 2024. Further, driven by the rise in the incidence of chronic diseases, surge in the ageing population and increasing adoption of digital technologies in healthcare, the digital biomarkers market is anticipated to grow at a CAGR of 18.5% during the forecast period. In terms of purpose of solution, the digital biomarker solutions market for monitoring is expected to capture the majority of market share during the forecast period.

Regional Analysis: North America to Hold the Largest Market Share in Digital Biomarkers Market

A majority of the digital biomarker companies are headquartered in North America, followed by those based in Europe. Consequently, nearly 40% of the digital biomarkers market is anticipated to be captured by the developers based in North America in 2035. Further, the digital biomarkers market in Asia-Pacific is expected to grow at a relatively higher CAGR during the forecast period (2024-2035).

Leading Digital Biomarkers Companies

Examples of key digital biomarkers companies (which have also been profiled in this report) include (in alphabetical order) AliveCor, BACtrack, Biogen, BioSensics, empatica, Eyenuk, Feel Therapeutics, icometrix, and Quibim.

Further, examples of other key players involved in the development of digital solutions for biomarkers include (in alphabetical order) Acculi Labs, ActiGraph, ATCOR, BioSerenity, iMediSync, IXICO, Kinsa, Koneksa Health, Kontigo Care, Progentec Diagnostics, and Vocalis Health.

Recent Developments in the Digital Biomarkers Market

Several recent developments have taken place in the field of digital biomarkers market, some of which have been outlined below. These developments, even if they took place post the release of the market report, substantiate the overall market trends that the analyst outlined in the analysis.

In January 2024, Quibim signed a product / technology integration agreement with Merck to develop ground-breaking precision medicine technologies targeting a wide range of oncological indications.

In November 2023, The Power of Digital Biomarkers 2023 conference was held in Paris, France. Several players, such as Empatica and Biogen, participated in the event to discuss the significance of digital biomarkers in improving treatment outcomes and enhancing patient satisfaction.

In April 2023, Aiforia Technologies raised a debt financing worth EUR 7.3 million from Business Finland in order to expand the existing features of their software offerings for accelerating business growth.

Digital Biomarkers Market Report Coverage

The digital biomarkers market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different geographies. One of the key objectives of this market report was to estimate the current market size, opportunity and the future potential of the global digital biomarkers market growth over the forecast period. The analyst has provided informed estimates on the likely evolution of the market during the forecast period, 2024-2035.

The year-wise projections of the current and future opportunity within the digital biomarkers market have been segmented based on relevant parameters, such as type of product (software / applications, wearables, sensors and gaming solutions), purpose of solution (diagnosis, early detection, monitoring, and predictive insights), type of biomarker (cognitive, idiosyncratic, physiological, vocal and others), therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health disorders, neurological disorders, respiratory disorders, substance abuse disorders and others), business model (B2B and B2C) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World).

In order to account for future uncertainties associated with some of the key parameters and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.

Digital Biomarkers Market Share Insights

The digital biomarkers market research report presents an in-depth analysis of various companies that are involved in the global digital biomarkers industry, across different segments, as defined below:

Historical Trend: 2018-2023

Base Year: 2023

Forecast Period: 2024-2035

Market Size 2024: USD 5.55 Billion

Market Size 2035: USD 35.84 Billion

CAGR: 18.5%

Type of Product:

Software / Applications



Gaming Solutions

Purpose of Solution:


Early Detection


Predictive Insights

Type of Biomarker:

Cognitive Biomarkers

Idiosyncratic Biomarkers

Physiological Biomarkers

Vocal Biomarkers

Other Biomarkers

Therapeutic Area:

Autoimmune Disorders

Cardiovascular Disorders

Infectious Diseases

Mental Health Disorders

Neurological Disorders

Respiratory Disorders

Substance Abuse Disorders


Business Model:



Key Geographical Regions:

North America



Middle East and North Africa (MENA)

Rest of the World

Key Companies Profiled:

Acculi Labs










Feel Therapeutics





Koneksa Health

Kontigo Care

Progentec Diagnostics


Vocalis Health

(Full list of 130+ companies captured is available in the report)

Excel Data Packs (Complimentary):

Market Overview

Product Competitiveness Analysis

Partnership and Collaboration Analysis

Funding and Investments Analysis

Global Events Analysis

Patent Analysis

Big Pharma Initiatives

Market Forecast and Opportunity Analysis

Key Attributes

Report Attribute

No. of Pages

Forecast Period

Estimated Market Value (USD) in 2024
$5.55 Billion

Forecasted Market Value (USD) by 2035
$35.8 Billion

Compound Annual Growth Rate

Regions Covered

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.